Search

Displaying results 2951 - 2960 of 9886 in total
  1. Drug

    Izilendustat

    go.drugbank.com/drugs/DB21532
    Experimental

    Izilendustat has a monoisotopic molecular weight of 433.18 Da. … Izilendustat is a small molecule drug. The usage of the INN stem '-dustat' in the name indicates that Izilendustat is a hypoxia inducible factor (HIF) prolyl hydroxylase inhibitor.

  2. Drug

    Civorebrutinib

    go.drugbank.com/drugs/DB21641
    Experimental

    Civorebrutinib has a monoisotopic molecular weight of 463.15 Da. … Civorebrutinib is a small molecule drug. The usage of the INN stem '-brutinib' in the name indicates that Civorebrutinib is a agammaglobulinaemia tyrosine kinase (Bruton tyrosine kinase) inhibitor.

  3. Drug

    Sofalcone

    go.drugbank.com/drugs/DB05197
    Experimental

    Sofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. on adherence, production of vacuolating toxin (VT), and induction of interleukin-8 (IL-8) secretion

  4. Drug

    Ancitabine

    go.drugbank.com/drugs/DB20595
    Experimental

    Ancitabine has a monoisotopic molecular weight of 225.07 Da. … Ancitabine is a small molecule drug.

  5. Drug

    Galocitabine

    go.drugbank.com/drugs/DB21373
    Experimental

    Galocitabine has a monoisotopic molecular weight of 439.14 Da. … Galocitabine is a small molecule drug.

  6. Drug

    Alpibectir

    go.drugbank.com/drugs/DB21561
    Investigational

    Alpibectir has a monoisotopic molecular weight of 332.1 Da. … Alpibectir is a small molecule drug.

  7. Drug

    Ceperognastat

    go.drugbank.com/drugs/DB21591
    Investigational

    Ceperognastat has a monoisotopic molecular weight of 383.14 Da. … Ceperognastat is a small molecule drug.

  8. Drug

    Ranosidenib

    go.drugbank.com/drugs/DB21727
    Investigational

    Ranosidenib has a monoisotopic molecular weight of 453.12 Da. … Ranosidenib is a small molecule drug. Ranosidenib is under investigation in clinical trial NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia).

  9. Drug

    Gadobutrol

    go.drugbank.com/drugs/DB06703
    ApprovedInvestigational

    Due to its physicochemical properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to other GBCA and thus requires a lesser injection volume. … [A7001] Like other GBCA, gadobutrol usage carries the risk of nephrogenic systemic fibrosis (NSF) due to the dissociation of gadolinium from the chelates, although gadobutrol tends to have a lower risk

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Entrectinib

    go.drugbank.com/drugs/DB11986
    ApprovedInvestigational

    [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.[A183929]

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index